Companies Cryptocurrencies
Beam Therapeutics Inc
Beam Therapeutics Inc
Exchange: NasdaqGS
IPO Date: 06/02/2020
CEO: Mr. John M. Evans
Biotechnology Healthcare 🔗
  • BEAM
  • 69.08
  • 4860096000
    market cap
  • 2.9900055
If you bought

shares of Beam Therapeutics Inc (BEAM) on
You would have made
Old Price $12 Current Price $12

Beam Therapeutics Inc. is a biotechnology company focused on developing precision genetic medicines based on its base editing technology, to providing life-long cures to patients suffering from diseases. Its base editing technology enables a new class of precision genetic medicines that targets a single base in the genome without making a double-stranded break in the deoxyribonucleic acid (DNA). It is advancing a broad, diversified portfolio of 12 base editing programs against distinct editing targets. Its programs are organized by delivery modality into three distinct pipelines: electroporation for delivery to blood cells and immune cells; lipid nanoparticles (LNPs), for non-viral in vivo delivery to the liver and potentially other organs in the future; and adeno-associated viral vectors (AAV), for viral delivery to the eye and central nervous system (CNS).

Address: 26 Landsdowne St Cambridge MASSACHUSETTS 02139

Stay updated.